ACTG A5142

ACTG A5142

• 批准号: 7603677
• 负责人: Jeffrey Lennox
• 金额: $ 0.04万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603677
• 关键词: AIDS clinical trial group; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Institution; Label; Lamivudine; Lopinavir/Ritonavir; Nucleosides; Phase; Protease Inhibitor; Randomized; Research; Research Personnel; Resources; Reverse Transcriptase Inhibitors; Ritonavir; Source; Stavudine; Tenofovir disoproxil fumarate; Treatment Protocols; United States National Institutes of Health; Upper arm; Zidovudine; base; compare effectiveness; efavirenz; non-nucleoside reverse transcriptase inhibitors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5142 is a phase III, randomized, three-arm, open-label study comparing the effectiveness of the following regimens for the initial treatment of HIV infection: Nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz [EFV] plus stavudine extended release [d4T XR] (or zidovudine [ZDV] or tenofovir disoproxil fumarate [TDF]) plus lamivudine [3TC]) Ritonavir (RTV)-enhanced protease inhibitor (PI)-based regimen (lopinavir/ritonavir [LPV/RTV] plus d4T XR [or ZDV or TDF] plus 3TC) Nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV plus LPV/RTV)

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 A5142是III期，随机，三臂开放标签研究，比较了以下方案对HIV感染初始治疗的有效性： 非核苷逆转录酶抑制剂（NNRTI）基于基于的方案（Efavirenz [efv] Plus Stavudine Extendend Extended ExtendendExement [D4T Xr]（或Zidovudine [ZDV]或替诺福韦DiSoprovir disoproxil fumarate [tddf] Plul lamivudine） 利托那韦（RTV）增强蛋白酶抑制剂（PI）基于基于的方案（Lopinavir/Ritonavir [LPV/RTV]加上D4T XR [或ZDV或TDF] Plus 3TC） 核苷逆转录酶抑制剂（NRTI） - 比较方案（EFV加LPV/RTV）